State Street’s Artiva Biotherapeutics ARTV Stock Holding History

State Street’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61M	Buy	165,764 +129,940	+363%	+$1.18M	﹤0.01%	3389
2026 Q1	$231K	Hold	35,824	–	–	﹤0.01%	3852
2025 Q4	$154K	Sell	35,824 -24,000	-40%	-$90.6K	﹤0.01%	3961
2025 Q3	$172K	Sell	59,824 -3,050	-5%	-$8.16K	﹤0.01%	3950
2025 Q2	$94.9K	Sell	62,874 -108,909	-63%	-$229K	﹤0.01%	3986
2025 Q1	$515K	Buy	171,783 +7,000	+4%	+$37.8K	﹤0.01%	3582
2024 Q4	$1.66M	Buy	164,783 +78,224	+90%	+$940K	﹤0.01%	3375
2024 Q3	$1.34M	Buy	+86,559	New	+$1M	﹤0.01%	3429

Other funds holding ARTV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

State Street's ARTV Position: Q2 2026 in Review

State Street increased its Artiva Biotherapeutics (ARTV) stake by 363% in Q2 2026, buying an estimated $1.18M and bringing the position to 165,764 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #3389.

State Street first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.66M in Q4 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

State Street held 165,764 shares of Artiva Biotherapeutics worth $1.61M as of Q2 2026.
State Street bought 129,940 Artiva Biotherapeutics shares in Q2 2026, an estimated $1.18M.
Artiva Biotherapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3389 holding.
State Street first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
State Street's Artiva Biotherapeutics position peaked at $1.66M in Q4 2024.
72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.